Jobs
-
The United States Patent and Trademark Office has issued a method of treatment patent to Aradigm for its inhaled nicotine formulations. US Patent No. 8,256,433, for Systems and Methods for Effecting Cessation of Tobacco Use,… Read more . . .
-
Rigel Pharmaceuticals says that it has begun a Phase 2 clinical study of its R343 nhaled SYK inhibitor that is being evaluated as a potential treatment for allergic asthma. The 8-week study, called SITAR (SYK… Read more . . .
-
Almirall has opened a new affiliate in Toronto, Canada. Having a presence in Canada will help the company roll out its recently approved aclidinium DPI for COPD, among other drugs, Almirall says. The company will… Read more . . .
-
A study by the Childhood Asthma Management Program (CAMP) Research Group published online in the New England Journal of Medicine on September 3 finds that children who received 400 μg of inhaled budesonide daily for… Read more . . .
-
The Federal Court of Australia has granted an injunction against Apotex, banning it from selling generic mometasone furoate nasal sprays in the country pending the outcome of a patent infringement lawsuit by Merck Sharpe &… Read more . . .
-
Pulmatrix has announced that Robert Clarke will succeed Robert Connelly as the company’s Chief Executive Officer. Clarke has been with the company, which is developing inhaled drugs based on its proprietary iSPERSE (inhaled small particles… Read more . . .
-
The FDA briefing materials for the September 5, 2012 meeting of the Anti-Infective Drugs Advisory Committee, which will consider the use of Novartis’s Tobi tobramycin inhalation powder (TIP) for the treatment of P. aeruginosa infections… Read more . . .
-
Elevation Pharmaceuticals, which is developing several inhalation products, has agreed to be acquired by Sunovion. Both boards have approved the deal. The agreement includes an upfront payment of $100 million and milestone payments for development… Read more . . .
-
Hovione has named Mike Ironside as General Manager of its Technology Transfer Center (TTC), which is located in New Jersey. Ironside was most recently with Anacor Pharmaceuticals and has previously worked for GSK and AMRI.… Read more . . .
-
According to Novartis, the latest Phase 3 study of the QVA149 indacaterol/glycopyrronium DPI demonstrated a significant reduction in exacerbations of moderate-to-severe COPD compared to the Seebri Breezhaler glycopyrronium bromide DPI alone. The company says that… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland